Back to top

Analyst Blog

Share price of CardioNet Inc. (BEAT - Snapshot Report), has been on the rise since this provider of ambulatory, continuous, real-time outpatient management solutions inked a three-year deal with UnitedHealthcare Insurance Company, a wing of UnitedHealth Group (UNH - Analyst Report).  Following the announcement, price of the stock shot up 55.45% (or $1.48) on Tuesday. The closing price of this medical technology stock of $4.99 represents an attractive year-to-date return of $127.85%.

On Jun 10, CardioNet gained coverage for its line of cardiac monitoring solutions. As per the National Provider Agreement effective Jul 1, 2013, UnitedHealthcare will cover CardioNet’s entire portfolio of monitoring modalities, encompassing the company’s well regarded Mobile Cardiac Outpatient Telemetry (MCOT) solution. Further, the agreement applies to all affiliated entities of UnitedHealthcare, encompassing Medicare and managed Medicaid plans.

CardioNet won coverage for its MCOT offering on the back of superior clinical data. Further, the application of MCOT is extendable to several indications.

This new deal that expands coverage for CardioNet appears to be lucrative as UnitedHealthcare presently covers over 70 million Americans. The agreement will ensure a substantial increase in the market which the company will serve with the inclusion of UnitedHealthcare’s nationwide network.

The deal with UnitedHealthcare triggered the bullish momentum for CardioNet as reflected in the 52-week high of $5.30 on Tuesday. We believe that the expanded coverage for its product platform should foster growth for the company.

Earlier, in April, CardioNet announced a structural change to support long-term growth. Management disclosed its plan to adopt a holding company structure and realign its adjacent business to leverage its growth profile. We look forward to these developments with full optimism.

Stocks to Consider

Medical stocks such as Haemonetics Corporation (HAE - Analyst Report), carrying a Zacks Rank #1 (Strong Buy) is worth considering. ArthroCare Corporation , carrying a Zacks Rank #2 (Buy) also warrants a look.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
THE PANTRY… PTRY 21.02 +2.09%
INTEL CP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%